Home > PJ > News / Daily News
Patients with rheumatoid arthritis survive longer if treated with methotrexate
Methotrexate could have a substantial survival benefit among patients with rheumatoid arthritis, American researchers conclude (Lancet 2002;359:1173).
The researchers prospectively studied 1,240 patients with rheumatoid arthritis. After adjusting for disease severity, methotrexate was found to have a 60 per cent survival benefit for all-cause mortality compared with those who did not use methotrexate, and a 70 per cent survival benefit for cardiovascular death.
The researchers comment: "Our data indicate that methotrexate may provide a substantial survival benefit, largely by reducing cardiovascular mortality. This gain in life expectancy could be considered in selecting a cost-effective, disease-modifying antirheumatic drug on a long-term basis."
Back to Top
Home | Journals | News | Notice-board | Search | Jobs Classifieds | Site Map | Contact us
©The Pharmaceutical Journal
Citation: The Pharmaceutical Journal